Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy

Duane, Steven F.; Peterson, Bruce A.; Bloomfield, Clara D.; Michels, Sheryl D.; Hurd, David D.

doi:10.1002/mpo.2950130410

Cited by 17 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient has been remarkably well after her standard treatment for leukaemia and is now in her fourth year of complete remission. The complete remission rate and survival of these patients with secondary ANNL has been disappointingly low,4 5 and prolonged remission is unusual. An approach using marrow transplantation as first line treatment seems more hopeful.67 The response to treatment of secondary leukaemia is generally so poor that patients rarely survive long enough to show signs of relapsed Hodgkin's disease.…”

Section: Discussionmentioning

confidence: 99%

Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

et al. 1994

View full text Add to dashboard Cite

Acute non-lymphocytic leukaemia is a well recognised and increasingly reported complication of treated Hodgkin's disease. The prognosis is generally poor with a disappointing response to chemotherapy. A patient in whom myelodysplastic features appeared after treatment for Hodgkin's disease, to be followed shortly afterwards by acute promyelocytic leukaemia, is reported. Complete remission was achieved and sustained until Hodgkin's disease reappeared three years later when the patient was autografted with a marrow harvested four years earlier. The patient remains in good health with platelet support at the time of writing.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

et al. 1994

View full text Add to dashboard Cite

show abstract

Treatment‐related leukemia in Hodgkin's disease: A multi‐institution study on 75 cases

Brusamolino

Papa

Valagussa

et al. 1987

Hematological Oncology

View full text Add to dashboard Cite

Hematological and cytogenetic characteristics of 75 cases of therapy-related acute non lymphoid leukemia (t-ANLL) occurring in Hodgkin's disease (HD) are analysed in this multi-institution study. Combined radio and chemotherapy had been given in 88 per cent of patients, either as adjuvant (44 per cent) or as salvage modality (44 per cent). Radiotherapy alone and chemotherapy alone had been given in 3 per cent and 9 per cent respectively. Eighty per cent of patients were in remission of HD and 71 per cent off-therapy while developing leukemia. The median latent time from remission of HD to leukemia was 34 months. The myeloblastic variety of leukemia accounted for 43 per cent of total cases; the myelomonocytic and monocytic for 17 per cent and 4 per cent, the promyelocytic and erythroblastic variants for 5 per cent and 7 per cent of t-ANLL. Twenty four per cent of cases were unclassifiable; one of these was TdT-positive. Dysplastic features of erythrocytic line were invariably present with circulating erythroblasts; defects of granulocytes, circulating megathrombocytes and micromegakaryocytes were also present. Bone marrow hypoplasia and marked fibrosis were documented in 47 per cent and 30 per cent of cases. Preleukemia heralded overt leukemia in 73 per cent of cases; 37 per cent had refractory anemia with no excess of blasts; 16 per cent of preleukemias were unclassifiable. Cytogenetics revealed chromosome abnormalities in 83 per cent of cases; 72 per cent presented chromosome 5 and/or 7 monosomy or partial deletion (5q- or 7q-) of the long arm (94 per cent in the combined modality therapy group). In 3 cases, a pure monosomy 7 was observed; in none 5q-alone. Response rate to conventional therapy was 14 per cent; low and high-dose cytarabine were of little benefit. Long-term CR (28 + and 16 + months) was achieved in 2 cases with allogeneic bone marrow transplantation (BMT) as first-line therapy. A better knowledge of t-ANLL in HD and new therapies, including BMT, may improve the prognosis of this late complication of intensive HD treatment.

show abstract

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Russell¹,

Houwen²,

Ruether³

et al. 1986

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

A 32-year-old woman developed acute monocytic leukemia within a year of treatment for Hodgkin's disease with chemotherapy and radiation. Residual leukemia was present in the bone marrow after two induction courses of high-dose Ara-C. She received a bone marrow transplant from an HLA- and DR-identical sister and remains in complete remission more than 2 years after transplantation. Only one other instance of a remission greater than 2 years after transplantation for secondary acute leukemia could be found in the literature. Although bone marrow transplantation may be carried out successfully in these patients, it is possible that they may be more vulnerable to transplant-related complications because of their previous exposure to chemotherapy and radiation. Only further study can clarify this matter and determine the best time for the procedure and which regimen should be used.

show abstract

Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy

Cited by 17 publications

References 25 publications

Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

Treatment‐related leukemia in Hodgkin's disease: A multi‐institution study on 75 cases

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Contact Info

Product

Resources

About